Research Analysts Set Expectations for BLFS Q1 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at HC Wainwright boosted their Q1 2026 earnings per share (EPS) estimates for BioLife Solutions in a research report issued to clients and investors on Monday, December 29th. HC Wainwright analyst Y. Chen now forecasts that the medical equipment provider will post earnings per share of ($0.02) for the quarter, up from their previous forecast of ($0.04). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at $0.03 EPS.

Several other research firms have also recently weighed in on BLFS. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, BioLife Solutions presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

BioLife Solutions Trading Down 1.8%

Shares of BioLife Solutions stock opened at $24.66 on Wednesday. The stock has a 50-day moving average price of $25.90 and a 200 day moving average price of $24.69. The company has a market cap of $1.19 billion, a P/E ratio of -352.24 and a beta of 1.93. BioLife Solutions has a 1 year low of $19.10 and a 1 year high of $29.62.

Institutional Trading of BioLife Solutions

Several large investors have recently made changes to their positions in BLFS. Comerica Bank raised its stake in shares of BioLife Solutions by 5.2% in the 1st quarter. Comerica Bank now owns 15,024 shares of the medical equipment provider’s stock valued at $343,000 after acquiring an additional 746 shares in the last quarter. State of Wyoming grew its holdings in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 1,490 shares during the last quarter. Royal Bank of Canada raised its position in shares of BioLife Solutions by 762.8% in the first quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock valued at $15,948,000 after purchasing an additional 617,320 shares during the period. Curi RMB Capital LLC lifted its stake in shares of BioLife Solutions by 1.1% in the first quarter. Curi RMB Capital LLC now owns 438,685 shares of the medical equipment provider’s stock worth $10,020,000 after buying an additional 4,870 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of BioLife Solutions during the 1st quarter worth $283,000. Institutional investors own 93.24% of the company’s stock.

Insider Transactions at BioLife Solutions

In related news, Director Joydeep Goswami sold 1,666 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $28.99, for a total transaction of $48,297.34. Following the transaction, the director owned 44,986 shares of the company’s stock, valued at approximately $1,304,144.14. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Troy Wichterman sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $25.72, for a total transaction of $771,600.00. Following the completion of the sale, the chief financial officer directly owned 152,769 shares of the company’s stock, valued at $3,929,218.68. This represents a 16.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 937,664 shares of company stock valued at $26,311,309 in the last ninety days. 2.20% of the stock is currently owned by insiders.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.